Skip to main content
Top
Published in: Virology Journal 1/2011

Open Access 01-12-2011 | Research

Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients

Authors: Madiha Akram, Muhammad Idrees, Shamail Zafar, Abrar Hussain, Sadia Butt, Samia Afzal, Irshad-ur Rehman, Ali Liaqat, Sana Saleem, Muhammad Ali, Azeem Butt

Published in: Virology Journal | Issue 1/2011

Login to get access

Abstract

Background

Current standard therapy commonly followed for chronic Hepatitis C Virus (HCV) in Pakistan is interferon alpha plus ribavirin combination therapy (IFN α/ribavirin) and pegylated interferon plus ribavirin (PegIFN/ribavirin). PegIFN/ribavirin has increased rate of sustained virological response than standard IFN α/ribavirin therapy. Objective of current study was to analyze rate of early and delayed response to antiviral treatment as well as rate of relapse response in patients following standard treatment IFN α/ribavirin and in patients following pegylated interferon treatment.

Methods

Baseline serum samples of 153 patients enrolled for IFN α/ribavirin and 50 patients for PegIFN/ribavirin were collected. After total RNA extraction, genotyping was and HCV RNA viral load was done. Subsequently HCV RNA viral load was estimated at 4 weeks of treatment, at 12 weeks, at 24 or 48 weeks and finally after 6 months follow up period. All the data was statistically analyzed using fisher's exact test.

Results

Total 86 patients out of 153 patients following conventional IFN α/ribavirin therapy completed treatment and 69% of them showed Rapid Virological Response (RVR). Whereas 50 patients following PegIFN/ribavirin treatment completed treatment and 80% of them achieved RVR. Total 64 out of 86 patients following IFN α/ribavirin therapy completed follow up period and 53.5% of them achieved Sustainded Virologcal Response (SVR). Forty-five out of total 50 patients who received PegIFN/ribavirin treatment completed 6 months follow up period and among these 70% achieved SVR. SVR rates were significantly associated with RVR (p < 0.001), age (p < 0.001) and gender (p < 0.01)

Conclusions

Rate of sustained virological response can be determined by factors like rapid virological response and age since they share significant association with one another. More over rate of SVR was more prominent in males than in females.
Appendix
Available only for authorised users
Literature
2.
go back to reference Kao JH, Chen DS: Transmission of hepatitis C virus in Asia: past and present perspectives. J Gastroenterol Hepatol 2000,15(Suppl):E91-96. 10.1046/j.1440-1746.2000.02108.xCrossRefPubMed Kao JH, Chen DS: Transmission of hepatitis C virus in Asia: past and present perspectives. J Gastroenterol Hepatol 2000,15(Suppl):E91-96. 10.1046/j.1440-1746.2000.02108.xCrossRefPubMed
3.
go back to reference Hoofnagle JH, di Bisceglie AM: The treatment of chronic viral hepatitis. N Engl J Med 1997, 336: 347-356. 10.1056/NEJM199701303360507CrossRefPubMed Hoofnagle JH, di Bisceglie AM: The treatment of chronic viral hepatitis. N Engl J Med 1997, 336: 347-356. 10.1056/NEJM199701303360507CrossRefPubMed
5.
go back to reference Fried MW, Hadziyannis SJ: Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. Semin Liver Dis 2004,24(Suppl 2):47-54.CrossRefPubMed Fried MW, Hadziyannis SJ: Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. Semin Liver Dis 2004,24(Suppl 2):47-54.CrossRefPubMed
6.
go back to reference Wohnsland A, Hofmann WP, Sarrazin C: Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 2007, 20: 23-38. 10.1128/CMR.00010-06PubMedCentralCrossRefPubMed Wohnsland A, Hofmann WP, Sarrazin C: Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 2007, 20: 23-38. 10.1128/CMR.00010-06PubMedCentralCrossRefPubMed
7.
go back to reference Idrees M, Riazuddin S: A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. BMC Gastroenterol 2009, 9: 5. 10.1186/1471-230X-9-5PubMedCentralCrossRefPubMed Idrees M, Riazuddin S: A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. BMC Gastroenterol 2009, 9: 5. 10.1186/1471-230X-9-5PubMedCentralCrossRefPubMed
8.
go back to reference Poordad F, Reddy KR, Martin P: Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis 2008, 46: 78-84. 10.1086/523585CrossRefPubMed Poordad F, Reddy KR, Martin P: Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis 2008, 46: 78-84. 10.1086/523585CrossRefPubMed
9.
go back to reference Yu ML, Chuang WL: Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009, 24: 336-345. 10.1111/j.1440-1746.2009.05789.xCrossRefPubMed Yu ML, Chuang WL: Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009, 24: 336-345. 10.1111/j.1440-1746.2009.05789.xCrossRefPubMed
10.
go back to reference Lee SS, Ferenci P: Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. Antivir Ther 2008,13(Suppl 1):9-16.PubMed Lee SS, Ferenci P: Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. Antivir Ther 2008,13(Suppl 1):9-16.PubMed
11.
go back to reference Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J: Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003, 38: 645-652.CrossRefPubMed Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J: Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003, 38: 645-652.CrossRefPubMed
12.
go back to reference Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Milotova V: Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995, 22: 1050-1056.CrossRefPubMed Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Milotova V: Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995, 22: 1050-1056.CrossRefPubMed
13.
go back to reference Jafri W, Subhan A: Hepatitis C in Pakistan: magnitude, genotype, disease characteristics and therapeutic response. Trop Gastroenterol 2008, 29: 194-201.PubMed Jafri W, Subhan A: Hepatitis C in Pakistan: magnitude, genotype, disease characteristics and therapeutic response. Trop Gastroenterol 2008, 29: 194-201.PubMed
14.
go back to reference Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med 2001, 345: 41-52. 10.1056/NEJM200107053450107CrossRefPubMed Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med 2001, 345: 41-52. 10.1056/NEJM200107053450107CrossRefPubMed
15.
go back to reference Idrees M: Development of an improved genotyping assay for the detection of hepatitis C virus genotypes and subtypes in Pakistan. J Virol Methods 2008, 150: 50-56. 10.1016/j.jviromet.2008.03.001CrossRefPubMed Idrees M: Development of an improved genotyping assay for the detection of hepatitis C virus genotypes and subtypes in Pakistan. J Virol Methods 2008, 150: 50-56. 10.1016/j.jviromet.2008.03.001CrossRefPubMed
16.
go back to reference Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998, 352: 1426-1432. 10.1016/S0140-6736(98)07124-4CrossRefPubMed Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998, 352: 1426-1432. 10.1016/S0140-6736(98)07124-4CrossRefPubMed
17.
go back to reference Soriano V, Peters MG, Zeuzem S: New therapies for hepatitis C virus infection. Clin Infect Dis 2009, 48: 313-320. 10.1086/595848CrossRefPubMed Soriano V, Peters MG, Zeuzem S: New therapies for hepatitis C virus infection. Clin Infect Dis 2009, 48: 313-320. 10.1086/595848CrossRefPubMed
18.
go back to reference Hadziyannis SJ, Papatheodoridis GV: Peginterferon-alpha2a (40 kDa) for chronic hepatitis C. Expert Opin Pharmacother 2003, 4: 541-551.PubMed Hadziyannis SJ, Papatheodoridis GV: Peginterferon-alpha2a (40 kDa) for chronic hepatitis C. Expert Opin Pharmacother 2003, 4: 541-551.PubMed
19.
go back to reference Zuberi BF, Zuberi FF, Memon SA, Qureshi MH, Ali SZ, Afsar S: Sustained virological response based on rapid virological response in genotype-3 chronic hepatitis C treated with standard interferon in the Pakistani population. World J Gastroenterol 2008, 14: 2218-2221. 10.3748/wjg.14.2218PubMedCentralCrossRefPubMed Zuberi BF, Zuberi FF, Memon SA, Qureshi MH, Ali SZ, Afsar S: Sustained virological response based on rapid virological response in genotype-3 chronic hepatitis C treated with standard interferon in the Pakistani population. World J Gastroenterol 2008, 14: 2218-2221. 10.3748/wjg.14.2218PubMedCentralCrossRefPubMed
20.
go back to reference Shin SR, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Yoo BC, Paik SW: Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response. J Gastroenterol Hepatol 2010, 25: 957-963.CrossRefPubMed Shin SR, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Yoo BC, Paik SW: Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response. J Gastroenterol Hepatol 2010, 25: 957-963.CrossRefPubMed
21.
go back to reference Munir S, Saleem S, Idrees M, Tariq A, Butt S, Rauff B, Hussain A, Badar S, Naudhani M, Fatima Z, Ali M, Ali L, Akram M, Aftab M, Khubaib B, Awan Z: Hepatitis C Treatment: current and future perspectives. Virol J 2010, 7: 296. 10.1186/1743-422X-7-296PubMedCentralCrossRefPubMed Munir S, Saleem S, Idrees M, Tariq A, Butt S, Rauff B, Hussain A, Badar S, Naudhani M, Fatima Z, Ali M, Ali L, Akram M, Aftab M, Khubaib B, Awan Z: Hepatitis C Treatment: current and future perspectives. Virol J 2010, 7: 296. 10.1186/1743-422X-7-296PubMedCentralCrossRefPubMed
Metadata
Title
Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
Authors
Madiha Akram
Muhammad Idrees
Shamail Zafar
Abrar Hussain
Sadia Butt
Samia Afzal
Irshad-ur Rehman
Ali Liaqat
Sana Saleem
Muhammad Ali
Azeem Butt
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2011
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-8-234

Other articles of this Issue 1/2011

Virology Journal 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine